| |
| | Business Wire: Michel A. Drouin, M.D., Joins Xanthus Life Scie... @ HighBeam Research (Site not responding. Last check: 2007-10-21) |
 | | Xanthus Life Sciences, a drug development company that is creating personalized anticancer medicines, today announced that Michel A. Drouin, M.D., has joined the company as Vice President, Clinical Research, effective immediately. |
 | | As head of the Canadian CR&D team of clinexcical scientists, regional clinical associates and administrative staff, Dr. Drouin was responsible for the conduct of Phase 1, 2 and 3 clinical trials in Canada for Wyeth Research. |
 | | Xanthus currently has three oncology drugs in its pipeline for four cancer indications - brain, breast, colon and prostate. |
| www.highbeam.com /library/doc0.asp?DOCID=1G1:104532459&refid=ip_encyclopedia_hf (482 words) |
|